Target | cis/trans | Study | SNP | SNP location | Maj/min allele | MAF | N | βinv | seinv | Pinv | fclog | Plog | Praw |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sE-Selectin | trans | Discovery | rs8176720 | 9:136,132,873 | T/C | 0.34 | 997 | 0.313 | 0.043 | 5.8×10-13 | 1.120 | 6×10-14 | 7.9×10-12 |
sE-Selectin | trans | Replication | rs12554580 | 9:136,128,603 | A/G | 0.41 | 337 | 0.224 | 0.072 | 0.002 | 1.100 | 0.002 | 0.012 |
ATS13 | cis | Discovery | rs8176720 | 9:136,132,873 | T/C | 0.34 | 997 | -0.277 | 0.044 | 6.4×10-10 | -1.060 | 2.3×10-10 | 2×10-9 |
ATS13 | cis | Replication | rs12554580 | 9:136,128,603 | A/G | 0.41 | 337 | -0.097 | 0.066 | 0.139 | -1.030 | 0.099 | 0.147 |
IR | trans | Discovery | rs8176720 | 9:136,132,873 | T/C | 0.34 | 997 | 0.280 | 0.045 | 7.4×10-10 | 1.070 | 9.7×10-9 | 7.8×10-6 |
IR | trans | Replication | rs12554580 | 9:136,128,603 | A/G | 0.41 | 337 | 0.323 | 0.058 | 6.8×10-8 | 1.120 | 5.1×10-8 | 5.2×10-6 |
inverse-normalized probe levels | log2 transformed probe levels | raw probe levels | |
---|---|---|---|
Discovery study | |||
Replication study |
inverse-normalized probe levels | log2 transformed probe levels | raw probe levels | |
---|---|---|---|
Discovery study | |||
Replication study |
Target (abbrv.) | sE-Selectin |
Target (full name) | E-Selectin |
Somalogic ID (Sequence ID) | SL001945 (3470-1_2) |
Entrez Gene Symbol | SELE |
UniProt ID | P16581 |
UniProt Comment |
|
Biomarker applications (based on IPA annotation) |
|
Pathway Interaction Database |
|
Reactome |
|
Pathway Studio |
|
Target (abbrv.) | ATS13 |
Target (full name) | A disintegrin and metalloproteinase with thrombospondin motifs 13 |
Somalogic ID (Sequence ID) | SL006610 (3175-51_5) |
Entrez Gene Symbol | ADAMTS13 |
UniProt ID | Q76LX8 |
UniProt Comment |
|
Reactome |
|
Target (abbrv.) | IR |
Target (full name) | Insulin receptor |
Somalogic ID (Sequence ID) | SL004125 (3448-13_2) |
Entrez Gene Symbol | INSR |
UniProt ID | P06213 |
UniProt Comment |
|
Targeted by drugs (based on IPA annotation) |
|
Biomarker applications (based on IPA annotation) |
|
Wiki Pathways |
|
Pathway Interaction Database |
|
Reactome |
|
Pathway Studio |
|
All locus annotations are based on the sentinel SNP (rs8176720) and 10 proxy variant(s) that is/are in linkage disequilibrium r2 ≥ 0.8. Linkage disequilibrium is based on data from the 1000 Genomes Project, phase 3 version 5, European population and was retrieved using SNiPA's Block Annotation feature.
Download the detailed results of SNiPA's block annotation (PDF)
Genes hit or close-by |
|
eQTL genes |
Trait | P | Study | Source |
---|---|---|---|
cg14440550 (chr9:136131142) | 3.3×10-310 | 10.1101/033084 (DOI) | BIOS QTL cis-meQTLs |
Plasma carcinoembryonic antigen (CEA) levels | 5.2×10-51 | 23300138 (PMID) | GRASP2 nonQTL |
Soluble intercellular adhesion molecule 1 (ICAM-1) | 4.8×10-22 | 21533024 (PMID) | GRASP2 nonQTL |
Anorexia nervosa | 5.6×10-22 | 24514567 (PMID) | Supplemental file |
Serum alkaline phosphatase levels | 3×10-21 | 24094242 (PMID) | GWAS Catalog via SNiPA |
LDL cholesterol | 1.6×10-17 | 24097068 (PMID) | Supplemental file |
Hemoglobin (Hb) | 1.4×10-12 | 23222517 (PMID) | GRASP2 nonQTL |
Alkaline phosphatase (ALP) | 4.3×10-12 | 18940312 (PMID) | GRASP2 nonQTL |
Triglycerides | 5.6×10-12 | 24097068 (PMID) | Supplemental file |
Red blood cell count (RBC) | 2.2×10-11 | 23222517 (PMID) | GRASP2 nonQTL |
Hematocrit (Hct) | 2.9×10-11 | 23222517 (PMID) | GRASP2 nonQTL |
Total cholesterol | 6.5×10-8 | 20686565 (PMID) | GRASP2 nonQTL |
ADpSGEGDFXAEGGGVR* | 2×10-7 | 24816252 (PMID) | gwas.eu via SNiPA |
Serum soluble E-selectin | 7.2×10-7 | 19729612 (PMID) | GRASP2 nonQTL |
E-selectin | 7.2×10-7 | pha002871 (dbGaP) | dbGaP via SNiPA |
Esophageal squamous cell carcinoma (Esophageal cancer) | 1.5×10-4 | 23300138 (PMID) | GRASP2 nonQTL |
This locus is discussed in the main paper. Here we report observations not mentioned in the paper: In Shin et al. [PubMed] SNP rs651007 associates with dipeptide levels (aspartylphenylalanine, p=2×10-7; X-14189, annotated as potential Leu-Ala, but Ser-Pro is also possible by mass alone, p=9.6×10-10; X14304, I/L-Ala or Ala-I/L?, p=1.8×10-8; X-14208, could be Cys-Met or Tyr-Ala or His-Pro or Ser-Phe by mass alone, p=1.5×10-7; X-14205; X14086: annotated as Thr-Glu, but mass is 25 too high; Val-Arg possible by mass alone). This SNP also associates in Raffler et al. [PubMed] (Urine NMR) with a signal at 2.0308 ppm (PM20308, p=5.1×10-20). It is also a marginal hit in CardioGram (7.1×10-8). He et al. [PubMed] report a genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk. The authors find strong association of SNP rs8176749 with carcinoembryonic antigen (CEA) levels – we find association with Cadherin-5. CD209 and MBL2 are both lectins. All associated ABO-associated proteins are glycoproteins, part of glycoprotein complex (LY96), or glycoprotein-binding (SELE), except for IL27RA (http://jcggdb.jp/rcmg/gpdb/index). According to Uniprot all proteins are glycoproteins (including associations non-replicated in QMDiab), while only half of all SomaLogic proteins are glycoproteins. The Panther classification system (http://pantherdb.org/tools/compareToRefList.jsp) reported a significant enrichment of the GO process "endothelial cell differentiation" (GO:0045446): 5 out of 17 annotated proteins were found (expected were 0.32, p=1.45×10-5).
Subnetwork of the ABO locus.Six replicated pQTLs at the ABO gene locus (red), including SNP identifiers that are linked to the the six loci (light green KORA SNPs, yellow QMDiab SNPs, bright green both), pQTLS (blue), proteins with significant partial correlation are connected, associations with GWAS endpoints are shown (grey) [NOTE: the anorexia is a false positive, checked this with the consortium].
The information gathered here is a result of an attempt to keep track of all interesting information that we encountered while investigating these loci. Please bear in mind that the annotation given here is neither complete nor free of errors, and that all information provided here should be confirmed by additional literature research before being used as a basis for firm conclusions or further experiments.